144 results
Page 4 of 8
8-K
EX-99.1
xp4n9cib2m69snr5t1jx
31 May 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
qyxfgk rbd
23 May 22
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:30pm
8-K
EX-99.1
b58ekvzj h2jxa
1 Feb 22
Kiora Pharmaceuticals Appoints Erin Parsons to its Board of Directors; Stephen From to Retire from Board
6:45am
8-K
EX-99.1
7d3xggad1wb9jc9ze6
11 Jan 22
Regulation FD Disclosure
12:00am
8-K
EX-99.1
ojyeh qu4560gwk
15 Dec 21
Kiora Pharmaceuticals Appoints David Hollander, MD, MBA, to its Board of Directors
7:00am
8-K
EX-99.1
o8ytircjqud6
14 Dec 21
Kiora Reports KIO-101 is Safe and Tolerable; Topline Data Supports Advancing KIO-101 to a Phase 2 Study in Patients with Dry Eye Disease
7:02am
8-K
EX-99.1
5udsiq
8 Nov 21
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s
7:32am
8-K
EX-2.1
dt0v drx31gm
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-99.1
uiz1z621s 79bk
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K
EX-99.1
dtv4avo29 qo1gmjea
14 Sep 21
Regulation FD Disclosure
4:20pm
8-K
EX-10.2
7qliw4o
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-99.1
1n7 vraoi
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am
8-K
EX-10.1
nofbhvwod 9u4nh9
10 Aug 21
EyeGate Announces $10.75 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
6:55am